Orthopedic gene therapy--lost in translation?

Area of Science:

• Orthopedics
• Gene Therapy
• Biotechnology

Background:

• Orthopedic gene therapy has been researched for 20 years with promising preclinical data.
• Despite potential, clinical translation remains limited, with no FDA-approved products.

Purpose of the Study:

• To examine the multifactorial reasons hindering clinical translation of orthopedic gene therapy.
• To identify barriers in funding, industry investment, intellectual property, and regulatory navigation.

Main Methods:

• Review of existing research and challenges in orthopedic gene therapy translation.
• Analysis of factors affecting academic funding, pharmaceutical investment, and startup environments.

Main Results:

• Clinical translation is hampered by high costs, lack of pharmaceutical funding due to safety perceptions, and complex intellectual property landscapes.
• Creating a collaborative environment among scientists, clinicians, and regulatory experts is difficult.

Conclusions:

• General constraints on biological therapy translation exist, similar to other fields.
• Recent successes in gene therapy may foster optimism for advancing orthopedic applications into clinical trials.